论文部分内容阅读
目的系统评价矮小症患儿生长激素受体外显子3多态性与重组人生长激素疗效的相关性。方法计算机检索Pubmed、EMbase、The CNKI、CBM、The Cochrane Library等中英文数据库,搜集有关应用重组人生长激素治疗生长激素缺乏症、特发性矮小症、Turner综合征、小儿胎龄儿的相关文献。根据Cochrane系统评价方法,进行文献资料收集、质量评价、数据提取,最后采用Revman 5.3软件以及stata12.0软件进行Meta分析。结果最终纳入17篇文献,Meta分析结果显示:rhGH治疗1年后,d3-GHR基因型身高生长速度明显高于GHRf1型,(MD=-0.75,95%CI(-0.96,-0.55),P<0.00001);而d3-GHR基因型身高标准差积分也同样高于GHRf1基因型(MD=-0.1 0SDS,95%CI(-0.18,~0.01),P=0.04)。结论在短期治疗中,d3-GHR基因型与rhGH助长效应具有一定相关性。
Objective To evaluate the relationship between the growth hormone receptor exon 3 polymorphism and the effect of recombinant human growth hormone in children with short stature. Methods The databases of Pubmed, EMbase, The CNKI, CBM and The Cochrane Library were searched by computer to collect the relevant literature on the use of recombinant human growth hormone therapy for growth hormone deficiency, idiopathic short stature, Turner syndrome and pediatric gestational age . According to the method of Cochrane systematic review, literature collection, quality evaluation and data extraction were carried out. Finally, Meta-analysis was performed using Revman 5.3 software and stata12.0 software. The results of the final inclusion of 17 articles, Meta analysis showed that: 1 year after rhGH treatment, d3-GHR genotype height growth rate was significantly higher than GHRf1 type (MD = -0.75,95% CI (-0.96, -0.55, P <0.00001). The height standard deviation integral of d3-GHR genotype was also higher than that of GHRf1 genotype (MD = -0.1 0SDS, 95% CI (-0.18, -0.01), P = 0.04). Conclusion In the short-term treatment, the genotype of d3-GHR has a certain correlation with the promoting effect of rhGH.